BioSpace News Archive

A federal judge ordered that information on sales of opioids up to the year 2013 could be released.

Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regions. Take a look.

Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration.

Karus Therapeutics Ltd, a clinical-stage biopharmaceutical company developing precision medicines for cancer, announced the appointment of Dr Hilary McElwaine-Johnn, MD as Chief Medical Officer with immediate effect.

Bacteria do not simply perish in hunger phases fortuitously; rather, the surrounding cells have a say as well.

With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.

Polyphor announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous for hospital-acquired and ventilator-associated bacterial pneumonia which have been put on a voluntary temporary hold on May 9th, 2019.

Vectura Group plc confirms its R&D investment priorities, announces a proposed £50 million capital return and provides an unaudited pre-close trading update.

Atriva Therapeutics GmbH announced that they have received the Biomarker Validation Award as part of the European Interreg Project Codex4SME.

Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company